Innovation, and economical and sustainability challenges are the main topics for pharmaceutical industries. Biocatalytical innovations (Exclusive Biocatalysts) meet the challenges through the design of novel synthesis routes that are cost efficient, save resources and reduce the carbon footprint. Beside these advantages, novel routes generate the potential for patent protection.
About 9 of 10 novel APIs are chiral. Enzymes are stereoselective and therefore are well suited for the synthesis of APIs or new chemical entities. Beside product innovations, the generic industry needs to bear a cost pressure by reducing manufacturing costs. Both challenges can be faced by the application of customised, highly efficient enzymatic solutions. c-LEcta applies its industry-tested technology platform to supply tailor-made enzymatic synthesis to the pharmaceutical industry.
We look forward to discussing your project ideas.